{Reference Type}: Journal Article
{Title}: A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.
{Author}: Mlakar V;Morel E;Mlakar SJ;Ansari M;Gumy-Pause F;
{Journal}: J Exp Clin Cancer Res
{Volume}: 40
{Issue}: 1
{Year}: Jun 2021 8
暂无{DOI}: 10.1186/s13046-021-01967-x
{Abstract}: Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcriptomics studies have demonstrated the RAS-MAPK pathway's contribution to the development and progression of neuroblastoma. This review compiles up-to-date evidence of this pathway's involvement in neuroblastoma. We discuss the RAS-MAPK pathway's general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling.